Meeting Coverage:

American Academy of Ophthalmology

AAO: 2023

Wet AMD Gene Therapy at 3 Years: Ixo-vec

Show Description +

Carl D. Regillo, MD, FACS, provides a look at 3-year data from the phase 1 OPTIC extension trial of ixoberogene soroparvovec (Ixo-vec [formerly ADVM-022], Adverum Biotechnologies)—and a peek at the phase 2 LUNA trial.

Posted: 11/08/2023

Up Next


Genetics: Now or Later

Inas Aboobakar, MD

Drug-Eluting IOLs

Kenneth Mandell, MD, PhD

Pearls for Subretinal Gene Therapy

Christina Y. Weng, MD, MBA

A CRISPR Gene Editing Update

Glenn Yiu, MD, PhD

A New Approach to Combatting Blindness in RP

Russell N. Van Gelder, MD, PhD

Diversity in Ocular Oncology

Basil K. Williams Jr, MD

Update on Glaucoma Lasers

Aaki Shukla, MD, and Mary Qiu, MD

Wet AMD Gene Therapy at 3 Years: Ixo-vec

Carl D. Regillo, MD, FACS, provides a look at 3-year data from the phase 1 OPTIC extension trial of ixoberogene soroparvovec (Ixo-vec [formerly ADVM-022], Adverum Biotechnologies)—and a peek at the phase 2 LUNA trial.

Posted: 11/08/2023


Please log in to leave a comment.

More From AAO: 2023 Coverage